Albumin-Bilirubin Grade and Hepatocellular Carcinoma Treatment Algorithm.
作者信息
Kudo Masatoshi
出版信息
Liver Cancer. 2017 Jun;6(3):185-188. doi: 10.1159/000462199. Epub 2017 Mar 9.
Abstract
摘要
相似文献
1
Albumin-Bilirubin Grade and Hepatocellular Carcinoma Treatment Algorithm.白蛋白-胆红素分级与肝细胞癌治疗算法
Liver Cancer. 2017 Jun;6(3):185-188. doi: 10.1159/000462199. Epub 2017 Mar 9.
2
Validation of the albumin-indocyanine green evaluation model in patients with resected hepatocellular carcinoma and comparison with the albumin-bilirubin score.验证白蛋白-吲哚菁绿评估模型在接受肝切除术的肝细胞癌患者中的应用，并与白蛋白-胆红素评分进行比较。
J Hepatobiliary Pancreat Sci. 2019 Jan;26(1):51-57. doi: 10.1002/jhbp.597. Epub 2019 Jan 16.
3
The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma.白蛋白-胆红素分级揭示了 HIV 相关肝细胞癌中肝储备与免疫功能障碍之间的预后关系。
Aliment Pharmacol Ther. 2018 Jan;47(1):95-103. doi: 10.1111/apt.14356. Epub 2017 Oct 16.
4
Comparison of albumin-bilirubin grade, platelet-albumin-bilirubin grade and Child-Turcotte-Pugh class for prediction of survival in patients with large hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.白蛋白-胆红素分级、血小板-白蛋白-胆红素分级和 Child-Turcotte-Pugh 分级在预测大肝癌患者经肝动脉化疗栓塞联合微波消融治疗后的生存情况中的比较。
Int J Hyperthermia. 2019;36(1):841-853. doi: 10.1080/02656736.2019.1646927.
5
Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades Accurately Predict Overall Survival in High-Risk Patients Undergoing Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma.白蛋白-胆红素及血小板-白蛋白-胆红素分级准确预测接受常规经动脉化疗栓塞术的高危肝细胞癌患者的总生存期。
J Vasc Interv Radiol. 2017 Sep;28(9):1224-1231.e2. doi: 10.1016/j.jvir.2017.05.020. Epub 2017 Jul 6.
6
Comparison of new prognostic systems for patients with resectable hepatocellular carcinoma: Albumin-Bilirubin grade and Albumin-Indocyanine Green Evaluation grade.可切除肝细胞癌患者新预后系统的比较：白蛋白-胆红素分级和白蛋白-吲哚菁绿评估分级
Hepatol Res. 2019 Oct;49(10):1218-1226. doi: 10.1111/hepr.13393. Epub 2019 Jul 10.
7
Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic.索拉非尼治疗肝细胞癌患者中白蛋白-胆红素分级对生存的影响：基于时间依赖的受试者工作特征分析。
J Gastroenterol Hepatol. 2019 Jun;34(6):1066-1073. doi: 10.1111/jgh.14564. Epub 2019 Feb 27.
8
Liver Function Assessment Using Albumin-Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation.使用白蛋白-胆红素分级对极早期肝细胞癌患者射频消融治疗后的肝功能评估
Dig Dis Sci. 2017 Nov;62(11):3235-3242. doi: 10.1007/s10620-017-4775-8. Epub 2017 Oct 5.
9
Platelet-albumin-bilirubin grade: Risk stratification of liver failure, prognosis after resection for hepatocellular carcinoma.血小板-白蛋白-胆红素分级：用于肝衰竭风险分层和肝癌切除术后预后的评估。
Dig Liver Dis. 2019 Oct;51(10):1430-1437. doi: 10.1016/j.dld.2019.04.006. Epub 2019 May 1.
10
Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma.在接受索拉非尼治疗的晚期肝细胞癌患者中，根据白蛋白-胆红素（ALBI）分级进行肝功能评估。
Invest New Drugs. 2015 Dec;33(6):1257-62. doi: 10.1007/s10637-015-0292-9. Epub 2015 Oct 14.
引用本文的文献
1
Liver function dynamics in advanced hepatocellular carcinoma receiving immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization.接受免疫检查点抑制剂和抗血管内皮生长因子抗体/酪氨酸激酶抑制剂治疗（无论是否联合经动脉化疗栓塞）的晚期肝细胞癌患者的肝功能动态变化
Ther Adv Med Oncol. 2025 Jun 30;17:17588359251347363. doi: 10.1177/17588359251347363. eCollection 2025.
2
Prediction Model of Survival in Unresectable HCC with Central Bile Duct Invasion Receiving TACE After Biliary Drainage: TEMP Score.经胆道引流后接受肝动脉化疗栓塞术的伴有肝门部胆管侵犯的不可切除肝细胞癌生存预测模型：TEMP评分
J Hepatocell Carcinoma. 2025 Mar 20;12:615-628. doi: 10.2147/JHC.S505328. eCollection 2025.
3
Prognostic Efficacy of the Albumin-Bilirubin Score and Treatment Outcomes in Hepatocellular Carcinoma: A Large-Scale, Multi-Center Real-World Database Study.白蛋白-胆红素评分对肝细胞癌的预后评估作用及治疗结局：一项大规模、多中心真实世界数据库研究
Liver Cancer. 2024 Jun 14;13(6):610-628. doi: 10.1159/000539724. eCollection 2024 Dec.
4
Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study.阿替利珠单抗联合贝伐珠单抗与索拉非尼治疗不可切除肝细胞癌患者的白蛋白-胆红素分级分析：III期IMbrave150研究的事后分析
Liver Cancer. 2023 Mar 4;12(5):479-493. doi: 10.1159/000529996. eCollection 2023 Oct.
5
Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma.新开发的改良ALBI分级对肝细胞癌显示出更好的预后和预测价值。
Liver Cancer. 2021 Dec 8;11(1):1-8. doi: 10.1159/000521374. eCollection 2022 Jan.
6
Prognostic Performance of Albumin-Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib.人工智能辅助下白蛋白-胆红素分级对经动脉化疗栓塞联合索拉非尼治疗的肝细胞癌的预后评估价值
Front Oncol. 2020 Dec 18;10:525461. doi: 10.3389/fonc.2020.525461. eCollection 2020.
7
Whole-liver transcatheter arterial chemoinfusion and bland embolization with fine-powder cisplatin and trisacryl gelatin microspheres for treating unresectable multiple hepatocellular carcinoma.应用细颗粒顺铂和三丙烯基明胶微球经肝动脉化疗栓塞术治疗不可切除的多发性肝细胞癌。
Jpn J Radiol. 2021 May;39(5):494-502. doi: 10.1007/s11604-020-01078-1. Epub 2021 Jan 2.
8
Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study.基线ALBI分级对接受乐伐替尼治疗的肝细胞癌患者预后的影响：一项多中心研究
Cancers (Basel). 2019 Jul 7;11(7):952. doi: 10.3390/cancers11070952.
9
Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function.白蛋白-胆红素分级在日本46681例肝细胞癌患者全国性调查中的验证、潜力及预后评估：对肝功能进行更详细评估的必要性
Liver Cancer. 2017 Nov;6(4):325-336. doi: 10.1159/000479984. Epub 2017 Sep 22.
本文引用的文献
1
Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications.作为日本肝脏学会肝癌循证临床实践指南一部分的白蛋白-胆红素（ALBI）分级：与肝损伤及Child-Pugh分级的比较
Liver Cancer. 2017 Jun;6(3):204-215. doi: 10.1159/000452846. Epub 2017 Mar 9.
2
Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade.使用白蛋白-胆红素分级对中期肝细胞癌进行新的亚组划分建议。
Oncology. 2016;91(3):153-61. doi: 10.1159/000447061. Epub 2016 Jul 1.
3
Incorporating albumin-bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma.将白蛋白-胆红素分级纳入意大利肝癌项目系统用于肝细胞癌。
J Gastroenterol Hepatol. 2017 Jan;32(1):221-228. doi: 10.1111/jgh.13457.
4
A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma.多中心比较 Child Pugh 评分和 Albumin-Bilirubin 评分在索拉非尼治疗肝细胞癌患者中的应用。
Liver Int. 2016 Dec;36(12):1821-1828. doi: 10.1111/liv.13170. Epub 2016 Jun 22.
5
Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade.肝功能对肝细胞癌根治性治疗的长期影响：ALBI分级的应用
Br J Cancer. 2016 Mar 29;114(7):744-50. doi: 10.1038/bjc.2016.33.
6
Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma.白蛋白-胆红素与 Child-Pugh 评分作为肝癌肝切除术后结局的预测指标。
Br J Surg. 2016 May;103(6):725-734. doi: 10.1002/bjs.10095. Epub 2016 Mar 23.
7
Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma.将白蛋白-胆红素（ALBI）评分纳入巴塞罗那临床肝癌（BCLC）系统用于肝细胞癌。
J Gastroenterol Hepatol. 2016 Jul;31(7):1300-6. doi: 10.1111/jgh.13291.
8
Surgical and Locoregional Therapy of HCC: TACE.肝癌的手术及局部区域治疗：经动脉化疗栓塞术
Liver Cancer. 2015 Sep;4(3):165-75. doi: 10.1159/000367739. Epub 2015 Jul 10.
9
Locoregional Therapy for Hepatocellular Carcinoma.肝细胞癌的局部区域治疗
Liver Cancer. 2015 Sep;4(3):163-4. doi: 10.1159/000367741. Epub 2015 Jun 5.
10
Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma.白蛋白-胆红素分级对2584例日本肝细胞癌患者预后评估的价值
J Gastroenterol Hepatol. 2016 May;31(5):1031-6. doi: 10.1111/jgh.13250.
Zotero 插件